Insmed price target raised to $213 from $211 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on Insmed (INSM) to $213 from $211 and keeps a Buy rating on the shares. The firm cites the company having reported positive top-line for ENCORE, its phase 3b evaluating Arikayce on top of SoC multidrug therapy in antibiotic naive MAC lung disease patients, adding that the data are robust, especially given the activate comparator azithromycin/ ethambutol, the analyst tells investors in a research note.